Polymorphism in protease and reverse transcriptase and phenotypic drug resistance of HIV-1 recombinant CRF02_AG isolates from patients with no prior use of antiretroviral drugs in Abidjan, Côte d'Ivoire [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 1, 2003, Pages 111-113

  Adjé Touré, Christiane ^a   Bilé, Célestin E ^a   Borget, Marie Yolande ^a   Hertog, Kurt ^b   Maurice, Chantal ^a   Nolan, Monica L ^a,c   Nkengasong, John N ^a,c  

^a Project RETRO CI Abidjan   (Côte d’Ivoire)

^b Virco BVBA   (Belgium)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; AMINO ACID SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LYMPHOCYTE COUNT; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS GENE; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; COTE D'IVOIRE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; POLYMORPHISM, GENETIC; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0041412769     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200309010-00016     Document Type: Letter

References (10)

1. Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS. 2003. In press.
2. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patient's response, survival and drug resistance. Lancet. 2002;360:34-40.
3. Adjé C, Cheingsong R, Roels T, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr. 2001; 26:501-506.
4. Pieniazek D, Rayfield M, Hu JD, et al. Protease from group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. AIDS. 2000;14:1489-1495.
5. Fonjungo PN, Mpoudi EN, Torimiro JN, et al. Human immunodeficiency type 1 group M protease in Cameroon: genetic diversity and protease inhibitor mutational features. J Clin Microbiol. 2002;40:837-845.
6. Vergne L, Peeters M, Mpoudi-Ngole E, et al. Genetic diversity of protease and reverse transcriptase sequences in non-B HIV-1 strains: evidence of many minor drug resistance mutations in treatment naive patients. J Clin Microbiol. 2000;38:3919-3925.
7. Toni T, Masquelier B, Bonard D, et al. Primary HIV-1 drug resistance in Abidjan (Côte d'Ivoire): a genotypic and phenotypic study. AIDS. 2002;16:488-490.
8. Hertogs K, de Béthune MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother. 1998;42:269-276.
9. Andrew J, Brown L, Heather MP, et al. Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J Virol. 2000;74:10269-10273.
10. Harrigan PR, Montaner JSG, Wegner SA, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS. 2001;15:1671-1677.